Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Human allogeneic adipose-derived mesenchymal adult stem cells are mesenchymal stem/stromal cells (MSCs) isolated from the adipose (fat) tissue of human donors, expanded in culture, and administered to unrelated patients[2][4][5]. These cells exhibit immunomodulatory, anti-inflammatory, and regenerative properties primarily via paracrine signaling—secreting cytokines, growth factors, and trophic factors that support tissue repair and modulate immune responses[2][3][5]. They are considered for treating a range of conditions including neurological disorders, type 1 and type 2 diabetes, Crohn's disease (particularly for complex perianal fistulas), subcutaneous tissue defects, wound healing, degenerative diseases, and certain cancers like glioblastoma[2][3][4][5]. Therapeutic administration may be via local (intratumoral), intrathecal, or intravenous routes[1][4][5]. Mayo Clinic is a noted developer and sponsor of recent clinical trials[4]. The product is not standardized internationally; its characterization and manufacturing vary, with current studies focused on safety, dose finding, and mechanistic profiling[2][4][5].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on human allogeneic adipose-derived mesenchymal adult stem cells.